Conditions: Prostatic Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1930
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.

Detailed description:

Arms:
arm 1: Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily arm 2: Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily

Interventions: intervention 1: Placebo intervention 2: Dasatinib intervention 3: Docetaxel intervention 4: Prednisone
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: